ES2229366T3 - Formulaciones medicinales en aerosol de formoterol. - Google Patents

Formulaciones medicinales en aerosol de formoterol.

Info

Publication number
ES2229366T3
ES2229366T3 ES97929756T ES97929756T ES2229366T3 ES 2229366 T3 ES2229366 T3 ES 2229366T3 ES 97929756 T ES97929756 T ES 97929756T ES 97929756 T ES97929756 T ES 97929756T ES 2229366 T3 ES2229366 T3 ES 2229366T3
Authority
ES
Spain
Prior art keywords
hfa
weight
aerosol
ethanol
formoterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97929756T
Other languages
English (en)
Spanish (es)
Inventor
Martin J. Oliver
Simon G. Paling
Philip A. Jinks
Sukhbinder K. Jaiswal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2229366(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Application granted granted Critical
Publication of ES2229366T3 publication Critical patent/ES2229366T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES97929756T 1996-06-11 1997-06-02 Formulaciones medicinales en aerosol de formoterol. Expired - Lifetime ES2229366T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9612297 1996-06-11
GBGB9612297.3A GB9612297D0 (en) 1996-06-11 1996-06-11 Medicinal aerosol formulations

Publications (1)

Publication Number Publication Date
ES2229366T3 true ES2229366T3 (es) 2005-04-16

Family

ID=10795182

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97929756T Expired - Lifetime ES2229366T3 (es) 1996-06-11 1997-06-02 Formulaciones medicinales en aerosol de formoterol.

Country Status (16)

Country Link
EP (2) EP0934057B1 (enExample)
JP (1) JP5000793B2 (enExample)
AR (1) AR009231A1 (enExample)
AT (1) ATE275940T1 (enExample)
AU (1) AU726382B2 (enExample)
CA (1) CA2257841C (enExample)
DE (1) DE69730723T2 (enExample)
DK (1) DK0934057T3 (enExample)
ES (1) ES2229366T3 (enExample)
GB (1) GB9612297D0 (enExample)
ID (1) ID19520A (enExample)
NO (1) NO320403B1 (enExample)
NZ (1) NZ333202A (enExample)
PT (1) PT934057E (enExample)
WO (1) WO1997047286A1 (enExample)
ZA (1) ZA974546B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6423298B2 (en) * 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
EA003960B1 (ru) * 1998-10-17 2003-10-30 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Устойчивый при хранении концентрат биологически активного вещества формотерола
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
CN1213732C (zh) * 2000-05-22 2005-08-10 奇斯药制品公司 用于加压计量吸入器的稳定药用溶液制剂
SE0004750D0 (sv) 2000-12-19 2000-12-19 Astrazeneca Ab Novel formulation
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
ATE267591T1 (de) 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
CA2495875C (en) * 2002-08-27 2010-06-22 Schering Corporation Process for producing metered dose inhaler formulations
AU2004246819A1 (en) * 2003-06-13 2004-12-23 Nycomed Gmbh Formoterol and ciclesonide combination
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
JP2007509147A (ja) * 2003-10-20 2007-04-12 シェーリング　コーポレイション 薬学的エアロゾル組成物
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP2077830B1 (en) * 2006-10-17 2012-11-07 Lithera, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
ES2774367T3 (es) 2009-05-29 2020-07-20 Pearl Therapeutics Inc Composiciones para el suministro respiratorio de agentes activos y métodos y sistemas asociados
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
HRP20140818T1 (hr) * 2009-10-02 2014-10-10 Chiesi Farmaceutici S.P.A. Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05508616A (ja) * 1989-02-23 1993-12-02 ローヌー　プーラン　ローラー　インターナショナル（ホウルディングス）インコーポレイテッド 治療用エアロゾル剤
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
SK140493A3 (en) * 1991-06-10 1994-10-05 Schering Corp Non-chlorofluorocarbon aerosol formulations
EP1277467B1 (en) * 1991-06-10 2006-09-20 Schering Corporation Non-chlorofluorocarbon aerosol formulations
DE69205177T2 (de) * 1991-12-12 1996-03-21 Glaxo Group Ltd., Greenford, Middlesex Pharmazeutische Aerosolformulierung.
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
EP0617610B1 (en) * 1991-12-18 1997-03-19 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
GB9207400D0 (en) * 1992-04-02 1992-05-13 Smithkline Beecham Plc Novel use
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
DE69730723T2 (de) 2005-10-06
WO1997047286A1 (en) 1997-12-18
EP1400239A1 (en) 2004-03-24
NO985720D0 (no) 1998-12-07
AU726382B2 (en) 2000-11-02
ATE275940T1 (de) 2004-10-15
PT934057E (pt) 2004-12-31
NZ333202A (en) 2000-06-23
EP0934057A1 (en) 1999-08-11
NO985720L (no) 1999-02-11
NO320403B1 (no) 2005-11-28
CA2257841C (en) 2008-05-20
AR009231A1 (es) 2000-04-12
AU3373997A (en) 1998-01-07
CA2257841A1 (en) 1997-12-18
EP0934057B1 (en) 2004-09-15
JP5000793B2 (ja) 2012-08-15
ZA974546B (en) 1998-11-23
GB9612297D0 (en) 1996-08-14
JP2000513340A (ja) 2000-10-10
ID19520A (id) 1998-07-16
DK0934057T3 (da) 2005-01-24
DE69730723D1 (de) 2004-10-21

Similar Documents

Publication Publication Date Title
ES2229366T3 (es) Formulaciones medicinales en aerosol de formoterol.
ES2325316T3 (es) Composiciones farmaceuticas para el tratamiento del asma.
ES2234266T3 (es) Formulaciones medicas para aerosoles.
ES2259447T3 (es) Formulaciones en aerosol medicinales que comprenden budesonida.
ES2077971T5 (es) Formulaciones medicinales en aerosol que comprenden salbutamol.
ES2358293T3 (es) Formulaciones de aerosol de diisobutirilapomorfina.
ES2267288T3 (es) Formulacion de aerosol medicinal.
ES2211108T3 (es) Formulaciones farmaceuticas para aerosoles con dos o mas sustancias activas.
ES2289832T3 (es) Composicion farmaceutica de aerosol que contiene hfa 227 y hfa 134a.
US6054488A (en) Medicinal aerosol formulations of formoterol
ES2249424T3 (es) Formulaciones que contienen un farmaco anticolinergico para el tratamiento de bronconeumopatias cronicas obstructivas.
JP4672143B2 (ja) 医薬用エーロゾル製剤
ES2199739T3 (es) Composiciones de aerosol.
ES2774367T3 (es) Composiciones para el suministro respiratorio de agentes activos y métodos y sistemas asociados
ES2343045T3 (es) Una formulacion medicinal en aerosol.
RU2294737C2 (ru) Медицинские аэрозольные составы
ES2234165T3 (es) Composiciones farmaceuticas en aerosol.
ES2472268T3 (es) Formulaciones de aerosol que comprenden fumarato de formoterol dihidratado, un propelente, etanol y opcionalmente un esteroide, en las que el fumarato de formoterol dihidratado tiene un contenido de agua del 4,8-4,28% en peso
CZ194797A3 (en) Pharmaceutical aerosol preparation, process of its preparation and use
ES2482106T3 (es) Formulaciones de aerosol que comprenden formoterol en suspensión
US20050207984A1 (en) Formoterol and ciclesonide aerosol formulations
US7105152B1 (en) Suspension aerosol formulations
KR100316358B1 (ko) 클로로플루오로카본 비함유 모메타손 푸로에이트 에어로졸 제형
ES2973882T3 (es) Formulaciones medicinales en aerosol mejoradas
US7101534B1 (en) Suspension aerosol formulations